Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
Latest Information Update: 11 May 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 06 Jul 2022 Status changed from active, no longer recruiting to completed.
- 09 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 09 Dec 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.